NCT05141682 2026-03-03
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1/2 Active not recruiting
Ohio State University Comprehensive Cancer Center
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Celgene
University of Birmingham